These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33363209)

  • 21. Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus.
    Zhang Y; Gao H; Hu X; Wang Q; Zhong F; Zhou X; Lin C; Yang Y; Wei J; Du W; Huang H; Zhou H; He W; Zhang H; Zhang Y; McCormick PJ; Fu J; Wang D; Fu Y; Lu X; Zhang T; Duan J; Qin B; Jiang H; Luo J; Zhang Y; Chen Q; Luo Q; Cheng L; Zhang Z; Zhang J; Li J
    J Virol; 2022 Jan; 96(1):e0125321. PubMed ID: 34586857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geraniin as a potential inhibitor of SARS-CoV-2 3CL
    Yu WD; Jin QY; Zeng MS; Liu JY; Xu PP
    Nat Prod Res; 2022 Dec; 36(23):6060-6063. PubMed ID: 35200071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
    Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
    F1000Res; 2020; 9():576. PubMed ID: 32802318
    [No Abstract]   [Full Text] [Related]  

  • 26. Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study.
    Wang H; Wen J; Yang Y; Liu H; Wang S; Ding X; Zhou C; Zhang X
    Front Pharmacol; 2022; 13():1036208. PubMed ID: 36467060
    [No Abstract]   [Full Text] [Related]  

  • 27. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.
    Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J
    J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection.
    Li H; Sun M; Lei F; Liu J; Chen X; Li Y; Wang Y; Lu J; Yu D; Gao Y; Xu J; Chen H; Li M; Yi Z; He X; Chen L
    Antiviral Res; 2024 Apr; 224():105841. PubMed ID: 38408645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral 3CL
    Behzadipour Y; Gholampour M; Pirhadi S; Seradj H; Khoshneviszadeh M; Hemmati S
    Int J Pept Res Ther; 2021; 27(4):2703-2716. PubMed ID: 34548852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potential bioactive natural compounds from Indonesian medicinal plants against 3-chymotrypsin-like protease (3CL
    Prasetyo WE; Purnomo H; Sadrini M; Wibowo FR; Firdaus M; Kusumaningsih T
    J Biomol Struct Dyn; 2023 Jul; 41(10):4467-4484. PubMed ID: 35470785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2.
    Lai YC; Cheng YW; Chao CH; Chang YY; Chen CD; Tsai WJ; Wang S; Lin YS; Chang CP; Chuang WJ; Chen LY; Wang YR; Chang SY; Huang W; Wang JR; Tseng CK; Lin CK; Chuang YC; Yeh TM
    Front Immunol; 2022; 13():868724. PubMed ID: 35603169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyphenolic Compounds Isolated from Marine Algae Attenuate the Replication of SARS-CoV-2 in the Host Cell through a Multi-Target Approach of 3CL
    Nagahawatta DP; Liyanage NM; Je JG; Jayawardhana HHACK; Jayawardena TU; Jeong SH; Kwon HJ; Choi CS; Jeon YJ
    Mar Drugs; 2022 Dec; 20(12):. PubMed ID: 36547933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repurposing immune boosting and anti-viral efficacy of
    Dinata R; Nisa N; Arati C; Rasmita B; Uditraj C; Siddhartha R; Bhanushree B; Saeed-Ahmed L; Manikandan B; Bidanchi RM; Abinash G; Pori B; Khushboo M; Roy VK; Gurusubramanian G
    J Biomol Struct Dyn; 2024; 42(1):43-81. PubMed ID: 37021347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
    Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
    J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
    Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
    In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4--The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS).
    St John SE; Tomar S; Stauffer SR; Mesecar AD
    Bioorg Med Chem; 2015 Sep; 23(17):6036-48. PubMed ID: 26190463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.
    Pourmand S; Zareei S; Shahlaei M; Moradi S
    Comput Biol Med; 2022 Jul; 146():105625. PubMed ID: 35688710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study on the mechanism of active components of Liupao tea on 3CL
    Ni WJ; Chen XX; Wei SY; Lan LL; Qiu RJ; Ling YP; Zhou DS; Wu ZM; Cao ZH; Yu CP; Zeng Y
    J Food Biochem; 2021 May; 45(5):e13707. PubMed ID: 33760271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.